Topera, Inc., a San Diego, CA-based medical device company that has developed a novel mapping and targeting system for the identification of the sources that sustain complex cardiac arrhythmias, including atrial fibrillation, completed a $25m Series C financing round.
The round was led by new investor New Enterprise Associates (NEA) with participation from a new strategic industry partner, existing investors and the company’s management team. In conjunction with the financing, NEA partner Justin Klein, M.D., joined Topera’s Board of Directors.
The company intends to use the capital to support the 2013 commercial launch of its RhythmViewTM WorkStation and FIRMapTM Catheter in Europe and the U.S., and to further advance its R&D pipeline and clinical development program.
Led by Edward Kerslake, CEO, Topera has developed a novel 3D analysis and mapping system to assist electrophysiologists in the identification of the electrical source of complex cardiac arrhythmias. The Topera System, which consists of the RhythmView Workstation and the FIRMap diagnostic catheter, is designed to enable electrophysiologists to view a dynamic representation of the electrical activity of the heart, supporting the diagnosis of and treatment planning for a variety of arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia, and ventricular tachycardia.